MAYPHARM Unveils HYALMASS AQUATOX, a Next-Generation Multi-Active Skin Solution for the Global Aesthetic Market

SEOUL, South Korea, Sept. 26, 2026 -- MAYPHARM, a global aesthetic and cosmeceutical company, has announced the upcoming launch of HYALMASS AQUATOX, which introduces a multi-active formulation designed to meet the demands of the global aesthetic market.

HYALMASS AQUATOX combines five active ingredients — PDRN, Exosomes, Botulinum Peptide, GHK-Cu, and Succinic Acid — into a single advanced aesthetic formulation rather than relying on just one trending ingredient.

The ingredients include Botulinum Peptide for achieving a smoother skin appearance, GHK-Cu for skin conditioning and regeneration, Succinic Acid for revitalization and antioxidant activity, PDRN associated with skin regeneration and recovery, and Exosomes, which are gaining recognition for their role in skin rejuvenation.

The launch follows the rising international interest in HYALMASS AQUA EXOSOME, furthering MAYPHARM's position in the global aesthetic market. As the demand for advanced skin rejuvenation products grows, the company has noted a rise in similar products adopting identical ingredient concepts and branding.

MAYPHARM stresses the importance of product authenticity and authorized distribution, encouraging distributors, aesthetic professionals, and customers to verify the manufacturer, supply channels, packaging, and official product information before purchasing or using HYALMASS products.